Tech Company Inital Public Offerings
Immuneering IPO
Immuneering was acquired by . Shares were listed on 7/30/2021.
Transaction Overview
Company Name
Announced On
7/30/2021
Transaction Type
IPO
Amount
$112,500,000
Proceeds Purpose
Use of proceeds for the Immuneering IPO are outlined in the company's S1 filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
245 Main St. 2nd Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Immuneering leverages more than a decade of leadership in bioinformatics to develop new medicines unlikely to be found by traditional drug discovery methods. Its current pipeline of drug candidates is focused on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Benjamin Zeskind
Chief Medical Officer
Scott Barrett
Chief Scientific Officer
Brett Hall
Co-Founder
Robert Carpenter
Vice President
Jason Funt
Vice President
Peter King
Vice President
Sarah Kolitz
Vice President
Andrew Lysaght
VP - Bus. Development
Rebecca Kusko
VP - R & D
Kevin Fowler
VP - R & D
Howard Kaufman
Browse more venture capital transactions:
Prev: 7/30/2021: Culture Amp venture capital transaction
Next: 7/30/2021: Prime Trust venture capital transaction
Share this article
Where The Data Comes From
We document all VC transactions involving tech companies. VC investment data records on this site come from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs